CD33 CAR-T (Shenzhen Geno-Immune Medical Institute)

CD33 CAR-T is an investigational chimeric antigen receptor (CAR) T-cell therapy developed by the Shenzhen Geno-Immune Medical Institute for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy involves the genetic modification of a patient's T cells using a lentiviral vector to express a CAR that specifically recognizes CD33 (also known as Siglec-3), a transmembrane glycoprotein highly expressed on the surface of AML blasts and myeloid progenitors. Upon intravenous infusion, these engineered T cells bind to CD33-positive cells, triggering T-cell activation and subsequent lysis of the leukemic cells. In clinical trials, this therapy is often evaluated as part of a multi-target strategy, combined with other CAR-T products targeting antigens like CLL-1 or CD123, to improve therapeutic efficacy and mitigate the risk of antigen-escape-mediated relapse.

Other names

CD33-specific CAR gene-engineered T cellsCD-33-specific CAR gene-engineered T cellsCD 33-specific CAR gene-engineered T cellsCD33-specific CAR-T cellsCD-33-specific CAR-T cellsCD 33-specific CAR-T cells